AWHL (Aspira Womens Health) EPS (Basic): $-0.25 (TTM As of Mar. 2026)

What is Aspira Womens Health EPS (Basic)?

Aspira Womens Health AWHL -15.44% 36 EPS (Basic) is $-0.25 as of Mar. 2026. GuruFocus rates AWHL with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Aspira Womens Health's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $0.02. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.25.

Aspira Womens Health's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.32.

Aspira Womens Health's EPS without NRI for the three months ended in Mar. 2026 was $-0.12. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.22.

During the past 3 years, the average EPS without NRI Growth Rate was 63.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 40.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 18.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Aspira Womens Health's highest 3-Year average EPS without NRI Growth Rate was 63.00% per year. The lowest was -21.20% per year. And the median was 20.50% per year.

Aspira Womens Health (OTCPK:AWHL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Aspira Womens Health EPS (Basic) Related Terms

Aspira Womens Health EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Aspira Womens Health's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspira Womens Health EPS (Basic) Chart

Aspira Womens Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

-4.27

-3.85

-1.81

-0.93

-0.37

Aspira Womens Health Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															-0.09	-0.07	-0.13	-0.07	0.02

36GF Score

Aspira Womens Health Inc AWHL

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Aspira Womens Health EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Aspira Womens Health's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-12.78	-	0)	/	34.103
	=	-0.37

Aspira Womens Health's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(0.676	-	0)	/	43.492
	=	0.02

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of $-0.25 mean?

Aspira Womens Health (AWHL) has a EPS (Basic) of $-0.25 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Aspira Womens Health and its competitors.

Is Aspira Womens Health's EPS (Basic) too high?

Aspira Womens Health's current EPS (Basic) is $-0.25. Overall, Aspira Womens Health has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Aspira Womens Health's EPS (Basic) compare to BIOQ and MBAI?

Aspira Womens Health's EPS (Basic) of $-0.25 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Medical Diagnostics & Research company?

A good EPS (Basic) depends on the Medical Diagnostics & Research industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Aspira Womens Health and its competitors. Aspira Womens Health's current EPS (Basic) is $-0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Aspira Womens Health stock overvalued right now?

Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.36 — trading 28.6% above its estimated fair value. The current EPS (Basic) is $-0.25. Aspira Womens Health's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current EPS (Basic) is $-0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspira Womens Health (AWHL) Overvalued in 2026?

Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued. The current stock price of $0.36 is trading 28.6% above its estimated GF Value™ of $0.28. GuruFocus considers Aspira Womens Health to be Significantly Overvalued.

Key valuation signals for AWHL:

EPS (Basic): $-0.25
GF Value™: $0.28 vs. price of $0.36 (28.6% above fair value)
GF Score™: 36/100 with 7 warning signs

No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspira Womens Health Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies BIOQ MBAI XWEL NDRA NOTV ADVB MDXH BIAF PRPO ISPC TMO DHR SHSE:603259 XSWX:LONN IDXX A WAT NTRA IQV ILMN

Address 12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.

36GF Score

Get the complete analysis for AWHL

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.36

Price

$0.28

GF Value

View AWHL Analysis

See EPS (Basic) data for all stocks →